2 completed, 1 active not recruiting, 1 no longer available, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Proteus Syndrome: new trials by email Literature Review of Proteus Syndrome trials Research Report on Proteus Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MK-7075 (Miransertib) in Proteus Syndrome MK-7075 (miransertib) - Proteus Syndrome | Phase 2 | Active not recruiting | National Human Genome Research Institute (NHGRI) | 38 | 2022-05-20 | 2026-07-17 |
| Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome MK-7075 (miransertib) - Proteus Syndrome | Phase 1 | Completed | National Human Genome Research Institute (NHGRI) | 6 | 2015-11-16 | 2022-06-30 |
| Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants Coronary Artery Disease, Proteus Syndrome | Completed | National Human Genome Research Institute (NHGRI) | 30 | 2011-05-29 | 2018-07-26 | |
| Study of Proteus Syndrome and Related Congenital Disorders Proteus Syndrome, PIK3CA Related Overgrowth Spectrum | Recruiting | National Human Genome Research Institute (NHGRI) | 1500 | 1994-04-27 | 2026-09-22 | |
| Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies ARQ 092 - Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS) | No longer available | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2021-08-06 |
Growth Disorders (2) · Abnormalities, Multiple (1) · Congenital Abnormalities (1) · Coronary Artery Disease (1) · Genetic Diseases, Inborn (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Hyperparathyroidism 2 (1)
Bone Diseases (5) · Bone Diseases, Developmental (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Hamartoma (5) · Hamartoma Syndrome, Multiple (5) · Limb Deformities, Congenital (5) · Musculoskeletal Abnormalities (5) · Musculoskeletal Diseases (5) · Neoplasms (5) · Neoplasms, Multiple Primary (5) · Abnormalities, Multiple (4) · Congenital Abnormalities (4) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Arterial Occlusive Diseases (1)
Miransertib (3)
National Human Genome Research Institute (NHGRI) (4) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1)
United States (4)
Leslie G Biesecker, M.D. (3) · Barbara B Biesecker (1)
PMID 34649967, PMID 30803705, PMID 35839129, PMID 42224880, PMID 42289769